Retractable Technologies, Inc. Results for the Periods Ended September 30, 2026
In 2026, purchasing patterns have been more consistent with historical trends, with the majority of flu season sales occurring in the third quarter. In contrast, in 2025, flu season sales were unusually high in the second quarter, affecting comparability.
We continue to lessen the financial impact of tariffs by producing certain products domestically and strategically ordering certain products from our Chinese suppliers. Domestic production comprised 40.3% of the units manufactured during the first nine months of 2026. Additionally, a reduction in force in
Our net losses for the three and nine months ended
Retractable reports the following results of operations for the three and nine months ended
Comparison of Three Months Ended
Domestic net sales accounted for 90.3% and 91.1% of total net sales for the three months ended
International net sales for the three months ended
Overall, unit sales increased 64.0% due to an increase in EasyPoint® needle sales.
Cost of manufactured product increased 69.9% compared to the same period last year primarily due to an increase in units sold during the period. Royalty expense increased 29% due to the increase in gross sales.
Tariffs may impact our costs in future periods. Approximately
Operating expenses decreased 18.9% primarily due to lower gross wages in the Sales and Marketing department and lower donation and credit loss expenses within General and administrative expenses.
The loss from operations was
The unrealized loss on debt and equity securities was
The provision for income taxes was
Comparison of Nine Months Ended
Domestic net sales accounted for 86.2% and 87.1% of total net sales for the nine months ended
International net sales for the nine months ended
Overall, unit sales increased 8.3%.
Cost of manufactured product increased 6.8% compared to the same period last year primarily due to an increase in units sold. The shift in product mix towards lower-margin products also contributed to the decrease in gross margin. Royalty expense remained consistent with the prior period.
Tariffs may impact our costs in future periods. Approximately
Operating expenses remained consistent with the prior period.
The loss from operations was
The unrealized loss on debt and equity securities was
The provision for income taxes was
ABOUT RETRACTABLE
Retractable manufactures and markets VanishPoint® and Patient Safe® safety medical products and the EasyPoint® needle. The VanishPoint® syringe, blood collection, and IV catheter products are designed to prevent needlestick injuries and product reuse by retracting the needle directly from the patient, effectively reducing exposure to the contaminated needle. Patient Safe® syringes are uniquely designed to reduce the risk of bloodstream infections resulting from catheter hub contamination. The EasyPoint® is a retractable needle that can be used with luer lock syringes, luer slip syringes, and prefilled syringes to give injections. The EasyPoint® needle also can be used to aspirate fluids and for blood collection. Retractable's products are distributed by various specialty and general line distributors.
For more information on Retractable, visit its website at www.retractable.com.
Forward-looking statements in this press release are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995 and reflect Retractable's current views with respect to future events. Retractable believes that the expectations reflected in such forward-looking statements are accurate. However, Retractable cannot assure you that such expectations will materialize. Actual future performance could differ materially from such statements.
Factors that could cause or contribute to such differences include, but are not limited to: tariffs; oil prices; material changes in demand; Retractable's ability to maintain liquidity; Retractable's maintenance of patent protection; Retractable's ability to maintain favorable third party manufacturing and supplier arrangements and relationships; foreign trade risk; Retractable's ability to access the market; production costs; the impact of larger market players in providing devices to the safety market; and other risks and uncertainties that are detailed from time to time in Retractable's periodic reports filed with the U.S. Securities and Exchange Commission.
View source version on businesswire.com: https://www.businesswire.com/news/home/20261116247636/en/
Retractable Technologies, Inc.
John W. Fort III, 888-806-2626 or 972-294-1010
Vice President, Chief Financial Officer, and Chief Accounting Officer
Source: Retractable Technologies, Inc.